Clinical Trial Update: Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing adjuvant regimens in operable breast cancer (MASTER): 6 cycles of docetaxel + cyclophosphamide or ACF followed by 3 cycles of docetaxel …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)
• FLUOROURACIL (Fluorouracil)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Fudan University | Conditions: Primary Breast Cancer | Phase 3 | Status: COMPLETED